Abstract: A grain-oriented electrical steel sheet of an embodiment of the present invention comprises Si: 1.0% to 7.0% and Y: 0.005% to 0.5% by wt %, and the remainder comprising Fe and other inevitable impurities, and 10 pieces or less of inclusions comprising Y and having a diameter of 30 nm to 5 ?m per area of 1 mm2.

Abstract: A nano spintronic device for using the spin current of a ferromagnetic material and the spin current of a heavy metal channel. The device includes a lower channel layer, a free layer, a pinned layer, an insulating film layer, and an upper channel layer. When current flows upon application of power, electrons are divided into +y-polarized spins and ?y-polarized spins in the lower channel layer, thereby generating torque in the free layer. The torque switches the magnetization direction of the free layer to an +y-axis direction or an ?y-axis direction so that the free layer stores magnetization information according to the magnetization direction. When current flows in the upper channel layer, the current flows into the pinned layer so that electrons in the pinned layer are divided into +y-polarized spins and ?y-polarized spins. The insulating layer insulates the free layer and the pinned layer from each other.

Abstract: The present invention relates to a biomarker composition for diagnosing and predicting prognosis of prostate cancer, and that the detection rate and expression level of gene combination composed with AR (Androgen receptor), AR-V7 (Androgen receptor variant 7), EpCAM (Epithelial cell adhesion molecule) in blood tumor cells (CTC) isolated from patients, Epithelial cell adhesion molecule), KRT-19 (Cytokeratin 19), PSA (Prostate specific antigen), and PSMA (Prostate specific membrane antigen) in circulating tumor cells (CTCs) isolated from patients is related to the level of malignancy in prostate cancer is confirmed and thus the gene combination provides as a biomarker for prostate cancer diagnosis and a biomarker for prognosis prediction of prostate cancer.

Abstract: The present invention relates to a brain cooling device for a craniotomy patient, and more specifically, to a brain cooling device for a craniotomy for cooling the brain so as to prevent damage to the brain after a brain surgery. To this end, the present invention provides the brain cooling device for a craniotomy patient comprising: a cooling portion which is buried in such a manner to come into contact with the brain or the dura mater; and one withdrawal tube, which is one end of the cooling portion that is exposed to the exterior, wherein the withdrawal tube is exposed to the exterior by penetrating through the scalp and the cranium.

Abstract: In a brain cooling device according to an embodiment of the present invention, preferably, temperature sensors are installed in one end and the other end of a cooling fluid transport tube to detect a temperature, a pressure measurement sensor is installed in a storage tank, a control unit is connected to the temperature sensors and the pressure measurement sensor, and the control unit calculates an amount of heat absorbed from a brain according to a change in pressure of the storage tank and the temperature detected by the temperature sensors. In the brain cooling device according to the embodiment of the present invention, preferably, one end of the cooling fluid transport tube and a drainage tube is bent such that adjacent drainage tubes come in close contact with each other.

Abstract: The present invention relates to a peptide that passes through a blood-brain barrier and binds specifically to apoptotic cells in neurodegenerative brain disease-affected sites, and uses thereof. Therefore, the peptide of the present invention can be used for detecting and imaging apoptotic cells in neurodegenerative brain disease-affected sites, and for targeted drug delivery and theranosis of neurodegenerative brain diseases.

Abstract: The present invention relates to stroke-targeting peptides and use thereof. More specifically, the present invention relates to a stroke-targeting peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 4 and use thereof. The peptide of the present invention can be specifically bound to stroke cells in the subject, and thus can be effectively used in diagnostic markers and kits for stroke, and compositions for drug delivery specific to stroke and pharmaceutical compositions and compositions for imaging stroke.

Abstract: The present invention relates to a peptide that passes through a blood-brain barrier and targets apoptosis of neurodegenerative brain disease-affected sites and uses thereof. More particularly, the present invention relates to a composition for delivering drugs to brain tissues, a composition for detecting apoptotic cells of neurodegenerative brain disease-affected sites, and a composition for imaging the neurodegenerative brain disease-affected sites which comprises a peptide having an amino acid sequence represented by SEQ ID: No. 1 respectively, and a composition for prevention, treatment, or theranosis of neurodegenerative brain diseases comprising said peptide. The peptide of the present invention can be used for detecting apoptosis in neurodegenerative brain diseases and further detecting apoptotic cells (especially apoptotic neuronal cells) in neurodegenerative brain disease-affected sites and imaging, targeted drug delivery, theranosis.

Abstract: The present invention relates to a composition comprising a starch or total dietary fiber which improves the cell viability, specifically, the inventive starch and total dietary fiber isolated from the extract of Gramineae plant and the components therefrom improved the cell viability when the cells were incubated under hypoxic condition, or in the presence of beta-amyloid and 6-hydroxydopamine treatment, as well as prevented and treated myocardiac infarction, cerebral infarction and vascular dementia, or alleviated memory loss, all of which were proven using rats as the respective animal models. Therefore, they can be used as therapeutics or health care food for preventing and treating ischemic diseases or degenerative brain diseases.

Abstract: The present invention relates to stroke-targeting peptides and use thereof. More specifically, the present invention relates to a stroke-targeting peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 4 and use thereof. The peptide of the present invention can be specifically bound to stroke cells in the subject, and thus can be effectively used in diagnostic markers and kits for stroke, and compositions for drug delivery specific to stroke and pharmaceutical compositions and compositions for imaging stroke.

Abstract: The present invention relates to a composition comprising a starch or total dietary fiber which improves the cell viability, specifically, the inventive starch and total dietary fiber isolated from the extract of Gramineae plant and the components therefrom improved the cell viability when the cells were incubated under hypoxic condition, or in the presence of beta-amyloid and 6-hydroxydopamine treatment, as well as prevented and treated myocardiac infarction, cerebral infarction and vascular dementia, or alleviated memory loss, all of which were proven using rats as the respective animal models. Therefore, they can be used as therapeutics or health care food for preventing and treating ischemic diseases or degenerative brain diseases.

Abstract: The present invention relates to a composition comprising extracts of Gramineae plant that improves cell viability under hypoxic conditions by inhibiting apoptosis. Thus, the extract of Triticum aestivum L., one of the Gramineae plant, of the present invention, in particular, prevents damage of brain, heart and kidney in animal models of ischemic diseases, and it also improves memory in an animal model of Alzheimer's disease. Therefore, a composition comprising extracts of Gramineae can be used as therapeutic agents or health care foods for preventing and treating ischemic diseases and degenerative brain diseases.

Abstract: The present invention relates to a composition comprising extracts of Gramineae plant that improves cell viability under hypoxic conditions by inhibiting apoptosis. Thus, the extract of Triticum aestivum L., one of the Gramineae plant, of the present invention, in particular, prevents damage of brain, heart and kidney in animal models of ischemic diseases, and it also improves memory in an animal model of Alzheimer's disease. Therefore, a composition comprising extracts of Gramineae can be used as therapeutic agents or health care foods for preventing and treating ischemic diseases and degenerative brain diseases.